Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
Volume 0.10M
Average 0.08M
VRCA Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Verrica Pharmaceuticals Inc.NASDAQ: VRCA
Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026
Deferred income tax outflow grows to $0
Q1 FY2026 deferred income tax was $0, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was $0.
Context
- Deferred income tax amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Deferred income tax increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly deferred income tax holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 66K | — |
Deferred Income Tax vs competitors
How VRCA compares with its peers on the latest reported figures
- VRCA's LTM Mar 2026 deferred income tax of $0 is the largest of the 5 companies compared; the peer median is $0.
- Deferred income tax amounts to 0.0% of revenue for VRCA, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding VRCA) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Depreciation & Amortization | 472K | 718K | 836K | 1.27M | 429K |
| Deferred Income Tax | 66K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.05M | 4.99M | 14.38M | 7.16M | 3.32M |
| Change in Working Capital | (535K) | (1.8M) | 9.86M | 2.03M | (6.25M) |
| Accounts Receivables | 0 | (487K) | (3.93M) | 4.34M | (5.32M) |
| Inventory | 0 | 487K | 0 | 0 | 0 |
| Accounts Payables | 497K | (338K) | 2.2M | (568K) | 176K |
| Other Working Capital | (1.03M) | (1.46M) | 11.59M | (1.74M) | (1.11M) |
| Other Non-Cash Items | 1.44M | 1.93M | 3.35M | 5.19M | 2.76M |
| Operating Cash Flow | (27.58M) | (18.65M) | (38.58M) | (60.93M) | (17.63M) |
| Capital Expenditures | (883K) | (302K) | (362K) | (27K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (68.91M) | (4.49M) | 0 | 0 | 0 |
| Sales of Investments | 69M | 59.01M | 0 | 0 | 0 |
| Other Investing Activities | (201K) | (180K) | 0 | 8K | 0 |
| Investing Cash Flow | (998K) | 54.04M | (362K) | (19K) | 0 |
| Debt Repayment | 4.97M | (43.75M) | 44.08M | (2.06M) | (48.2M) |
| Common Stock Issued | 28.12M | 26.9M | 30.3M | 39.64M | 50.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 558K | (17K) | (169K) | 155K | (420K) |
| Financing Cash Flow | 33.65M | (16.87M) | 74.21M | 37.73M | 1.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.07M | 18.52M | 35.27M | (23.22M) | (16.18M) |
| Free Cash Flow | (28.47M) | (18.95M) | (38.94M) | (60.95M) | (17.63M) |
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
Intrinsic Alpha fair value
Locked
Current Price
$3.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.